What Kind Of Investors Own Most Of Gain Therapeutics, Inc. (NASDAQ:GANX)? Gain Therapeutics is a small cap stock, so it might not be well known by many institutional investors. One of the largest shareholder is Khalid Islam (who also holds the title of Top Key Executive) with 7.4% of shares outstanding. Its usually considered a good sign when insiders own a significant number of shares in the company, and in this case, we're glad to see a company insider play the role of a key stakeholder. Eric Richman, the CEO has 1.8% of the shares allocated to their name.
Gain Therapeutics’ lead compounds are allosteric modulators of glucocerebrosidase. This enzyme, encoded by the GBA1 gene, is defective in Gaucher disease, a lysosomal storage disorder that results in the toxic accumulation of substrates in organs. The company’s lead compounds are very brain-penetrant and so “could overcome some of the limitations of current Gaucher disease therapies that don’t alleviate brain, bone and cartilage pathology,” says Gain’s scientific advisor Joanne Taylor. Yet the first port of call for clinical trials will be in Parkinson’s disease, as the GBA1 gene is mutated in about 10% of those with the disease. A phase 1 trial is anticipated to start later this year, with the Gaucher trial initiating soon after.
Podcast:
The first BioTalk listed above is really good. Here are three more podcast worth listening to.
DISCLOSURE: Preclinical Biotech
Please research the risk involved w/ investing. There are many articles on the HOME and BIOTECH tab. Please watch the videos, read the articles, consider your risk tolerance in relations to your personal financial health, and articulate your goals taking into account the actual Risk:Reward Ratio of any investment.
Please research the risk involved w/ investing. There are many articles on the HOME and BIOTECH tab. Please watch the videos, read the articles, consider your risk tolerance in relations to your personal financial health, and articulate your goals taking into account the actual Risk:Reward Ratio of any investment.
This section below doesn't have anything to do w/ GANX. I first heard about Kuru Disease during a segment on NPR and was fascinated by it. Later I met people who studied proteins and a MD who had a patient w/ prions. The thought of scientists from the past having access to supercomputers such as those available for Gain Therapeutics and their SEE-Tx target identification platform, is just something amazing to imagine!
The group, which won a Nobel Prize for the findings, dubbed it a "slow virus."
But it wasn't a virus — or a bacterium, fungus, or parasite. It was an entirely new infectious agent, one that had no genetic material, could survive being boiled, and wasn't even alive. As another group would find years later, it was just a twisted protein, capable of performing the microscopic equivalent of a Jedi mind trick, compelling normal proteins on the surface of nerve cells in the brain to contort just like them. The so-called "prions," or "proteinaceous infectious particles," would eventually misfold enough proteins to kill pockets of nerve cells in the brain, leaving the cerebellum riddled with holes, like a sponge.